Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits
- PMID: 25775192
- DOI: 10.1089/jop.2014.0140
Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits
Abstract
Purpose: The primary objective of this study was to compare uptake and distribution of the commercially available formulation of 0.2% olopatadine and the newly developed 0.77% olopatadine hydrochloride ophthalmic solution formulation with improved solubility following a single (30 μL), bilateral topical ocular dose in male New Zealand white rabbits.
Methods: Each animal received a single 30-μL topical ocular dose (0.2% olopatadine or 0.77% olopatadine hydrochloride ophthalmic solution) to the right (OD) eye followed by the left (OS) eye for a total dose of 60 μL. Olopatadine concentrations were measured in ocular tissues (cornea, bulbar, conjunctiva, choroid, iris-ciliary body, whole lens, retina), aqueous humor, and plasma at prespecified time points over 24 h using a qualified liquid chromatography coupled with mass spectrometry (LC-MS/MS) analytical method.
Results: Olopatadine was absorbed into the eye and reached maximal levels (Cmax) within 30 min (0.5 h) to 2 h (Tmax) in ocular tissues and plasma for both treatment groups, except for the lens in which the Tmax was 4 h in the 0.2% olopatadine group and 8 h in the 0.77% olopatadine hydrochloride group, respectively. Tissues associated with the site of dosing, that is, the conjunctiva and cornea, had the highest concentrations of olopatadine in both the 0.2% olopatadine (609 and 720 ng/g) and 0.77% olopatadine hydrochloride (3,000 and 2,230 ng/g) dose groups. The greatest differences between 0.2% olopatadine and 0.77% olopatadine hydrochloride were associated with the overall duration and level of ocular exposures.
Conclusions: The newly developed 0.77% olopatadine hydrochloride ophthalmic solution formulation resulted in a higher and more prolonged olopatadine concentration in the target tissue, that is, conjunctiva compared to the commercial formulation of 0.2% olopatadine ophthalmic solution.
Similar articles
-
Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.J Ocul Pharmacol Ther. 2014 Feb;30(1):66-73. doi: 10.1089/jop.2013.0142. Epub 2013 Dec 10. J Ocul Pharmacol Ther. 2014. PMID: 24325539 Clinical Trial.
-
Ocular pharmacokinetics profile of different indomethacin topical formulations.J Ocul Pharmacol Ther. 2011 Dec;27(6):571-6. doi: 10.1089/jop.2011.0120. Epub 2011 Nov 7. J Ocul Pharmacol Ther. 2011. PMID: 22059858
-
Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.J Ocul Pharmacol Ther. 2019 Sep;35(7):395-402. doi: 10.1089/jop.2018.0106. Epub 2019 Aug 6. J Ocul Pharmacol Ther. 2019. PMID: 31355703 Free PMC article.
-
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.Expert Opin Pharmacother. 2017 Aug;18(11):1137-1143. doi: 10.1080/14656566.2017.1346085. Epub 2017 Jul 9. Expert Opin Pharmacother. 2017. PMID: 28656804 Review.
-
Ion Channels in the Eye: Involvement in Ocular Pathologies.Adv Protein Chem Struct Biol. 2016;104:157-231. doi: 10.1016/bs.apcsb.2015.11.006. Epub 2015 Dec 31. Adv Protein Chem Struct Biol. 2016. PMID: 27038375 Review.
Cited by
-
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis.Clin Ophthalmol. 2017 Jun 8;11:1089-1097. doi: 10.2147/OPTH.S131830. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28652694 Free PMC article.
-
Time-course changes in DNA damage of corneal epithelial cells in rabbits following ocular instillation with genotoxic compounds.Genes Environ. 2022 May 9;44(1):14. doi: 10.1186/s41021-022-00243-4. Genes Environ. 2022. PMID: 35527291 Free PMC article.
-
DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs.Br J Pharmacol. 2018 Oct;175(20):3891-3910. doi: 10.1111/bph.14458. Epub 2018 Sep 17. Br J Pharmacol. 2018. PMID: 30051467 Free PMC article.
-
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2.J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):593-605. doi: 10.1007/s10928-018-9588-7. Epub 2018 Apr 21. J Pharmacokinet Pharmacodyn. 2018. PMID: 29680872 Free PMC article. Clinical Trial.
-
Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies.Clin Ophthalmol. 2017 Apr 10;11:669-681. doi: 10.2147/OPTH.S126690. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28435218 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical